Fondaparinux anti-Xa activity: a comparison of one clotting assay and chromogenic substrate assays.

被引：0
|
作者：
Van Dreden, P
Depasse, F
Gerotziafas, GT
Busson, J
Fontaine, S
Samama, MM
机构：
[1] Serbio Labs, Gennevilliers, France
[2] LCL, Ivry, France
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4191
引用
收藏
页码：120B / 121B
页数：2
相关论文
共 50 条
  • [21] The relationship between anti-Xa activity and complications in orthopaedic patients receiving prophylactic fondaparinux
    Matsumoto, T.
    Wada, H.
    Masahiro, H.
    Wakebayashi, H.
    Yoshida, K.
    Miyamoto, N.
    Ohishi, K.
    Shimokariya, Y.
    Yamada, N.
    Sudo, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 689 - 689
  • [22] Monitoring for anti-Xa activity for prophylactic administration of Fondaparinux in patients with artificial joint replacement
    Yoshida, Kakunoshin
    Wada, Hideo
    Hasegawa, Masahiro
    Wakabayashi, Hiroki
    Ando, Honami
    Oshima, Seika
    Matsumoto, Takeshi
    Shimokariya, Yuji
    Noma, Katsura
    Yamada, Norikazu
    Uchida, Atsumasa
    Nobori, Tsutomu
    Sudo, Akihiro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2011, 94 (04) : 355 - 360
  • [23] THE EFFECTS OF POST-HEPARIN PLASMA LIPASES ON ANTI-XA CLOTTING ACTIVITY
    WILLIAMS, SP
    BARROWCLIFFE, TW
    THROMBOSIS RESEARCH, 1985, 37 (03) : 371 - 377
  • [24] A comprehensive evaluation of factors effecting range and precision for heparin Anti-IIa and Anti-Xa chromogenic assays
    Shaklee, P.
    Shaklee, M. J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 1092 - 1092
  • [25] Preliminary performance data of a new chromogenic direct anti-Xa assay evaluated for the quantification of Rivaroxaban
    Pilgrim, S.
    Esch, V
    Kolbe-Scheu, K.
    Krumpholz, B.
    Schleifer, M.
    Lichte, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 532 - 532
  • [26] Comparison of 8 commercial Anti-Xa assays and the heparin assay by protamine titration in patients receiving unfractionated heparin
    Theaker, J
    Kitchen, S
    Philips, JK
    Preston, FE
    THROMBOSIS AND HAEMOSTASIS, 1997, : P1133 - P1133
  • [27] Pharmacokinetics of antixa-activity of LMWH measured by chromogenic substrate and clotting assays
    Haas, SK
    Calatzis, A
    Calatzis, A
    Stemberger, A
    Esslinger, HU
    Bacher, P
    THROMBOSIS AND HAEMOSTASIS, 1999, : 491 - 491
  • [28] Heparin-calibrated chromogenic anti-Xa assays are not suitable to assess the presence of significant direct factor Xa inhibitors levels
    Sabor, Lina
    Raphael, Melanie
    Dogne, Jean-Michel
    Mullier, Francois
    Douxfils, Jonathan
    THROMBOSIS RESEARCH, 2017, 156 : 36 - 38
  • [29] Discordance between the neutralization profile of apixaban, betrixaban, edoxaban and rivaroxaban in the clotting assays and anti-Xa measurements
    Siddiqui, Fakiha
    Tafur, Alfonso
    Hoppensteadt, Debra
    Jeske, Walter
    Lewis, Bruce
    Fareed, Jawed
    FASEB JOURNAL, 2020, 34
  • [30] STRUCTURAL FEATURES OF HEPARIN VARIANTS HAVING HIGH ANTI-XA CLOTTING-ACTIVITY
    FRANSSON, LA
    HAVSMARK, B
    NIEDUSZYNSKI, IA
    HUCKERBY, TN
    LEWIS, WE
    CARBOHYDRATE RESEARCH, 1982, 104 (01) : 139 - 146
12345